J&J Sees Strong 2026 Growth Despite Deal to Cut Prices

Johnson & Johnson lost a key battle to block experts linking the company’s withdrawn baby powder products to cancer from testifying in court, sending shares lower.

The legal development overshadowed an upbeat fourth-quarter sales update, in which the company surpassed expectations on strong growth for several newer cancer treatments. It also issued higher-than-expected 2026 guidance.